#China #Shanghai #WuXi AppTec #2025 financials #SCRDMO

WuXi AppTec Achieves Exceptional Financial Milestones for 2025

WuXi AppTec, a leading global player in the pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization) sector, has successfully reported record financial results for the year ending December 31, 2025. The company achieved remarkable growth, significantly surpassing their own yearly guidance.

In the reported year, WuXi AppTec’s total revenue soared to RMB 45.46 billion, marking a robust increase of 15.8% compared to the previous year. Specifically, revenue from continuing operations reached RMB 43.42 billion, which is an impressive 21.4% growth year-on-year. This growth reflects the company’s strategic investments in capacity expansion and efficiency improvements, which allowed them to meet and exceed customer demand effectively.

One of the standout indicators of WuXi AppTec’s performance was the significant rise in adjusted non-IFRS net profit, which surged by 41.3% year-on-year to reach RMB 14.96 billion. This translated into an adjusted non-IFRS net profit margin of 32.9%, up by 5.9 percentage points from the previous year, showcasing the company’s strong operational management and financial health. Furthermore, the adjusted diluted earnings per share (EPS) also experienced a 41.4% increase, reaching RMB 5.16, signaling further shareholder value creation.

The company's robust financial standing is further highlighted by its backlog for continuing operations, which increased by 28.8% year-on-year to RMB 58.00 billion, thereby ensuring a solid foundation for future revenue generation. In addition, adjusted operating cash flow rose dramatically by 39.1% to RMB 16.67 billion, underscoring the sustainability of WuXi AppTec's business growth.

Strategic Focus and Global Expansion

WuXi AppTec's ability to sustain this upward trajectory can be attributed to its comprehensive and fully integrated CRDMO platform. The company's well-defined strategies, “follow the molecule” and “win the molecule”, guided their operations, particularly in the development and manufacturing of small molecules. In 2025 alone, the company added 839 new molecules to its small molecule Development and Manufacturing (DM) pipeline, which totaled 3,452 by year-end. Additionally, commercial and phase III projects also saw an increase, reflecting strong market demand and operational execution.

Moving forward, WuXi AppTec is committed to enhancing its global presence and expanding its capacity. The company successfully passed FDA inspections at several sites, including Changzhou, Taixing, and Jinshan API locations, without any observations. As a result, the total reactor volume for small molecule APIs surpassed 4,000 kL, with an impressive reactor volume of Solid Phase Peptide Synthesizers exceeding 100,000 L.

Commitment to Sustainability and Quality Compliance

WuXi AppTec has also demonstrated a strong commitment to sustainability, as evidenced by the attainment of notable ratings such as MSCI “AAA” and CDP Climate Change “A” in 2025. The company actively engages in initiatives to reduce greenhouse gas emissions and strives to integrate sustainable practices into its operations. Recognizing their responsibility as a UNGC participant and PSCI Supplier Partner, WuXi is dedicated to creating both value for shareholders and positive contributions to the environment.

Quality assurance remains a top priority for WuXi AppTec. The company successfully completed 741 quality audits and inspections conducted by global clients and authorities in 2025, with no critical findings, which showcases their dedication to upholding high standards of compliance.

Looking Ahead: Future Prospects for 2026

As WuXi AppTec looks toward 2026, the company anticipates continued robust growth, projecting total revenue between RMB 51.3 billion to RMB 53.0 billion. They expect revenue from continuing operations to achieve a year-on-year growth of 18-22%. With proposed capital expenditures of RMB 6.5 to 7.5 billion, WuXi AppTec remains eager to invest in its infrastructure, talent acquisition, and enhanced operational capabilities.

In a statement, Dr. Ge Li, Chairman and CEO of WuXi AppTec, expressed confidence in the company’s growth trajectory, noting, “In 2025, WuXi AppTec achieved record performance with strong growth in revenue and profit. Our backlog for continuing operations reached RMB 58.0 billion, demonstrating the strength of our unique CRDMO business model.”

Moreover, the company has proposed a cash dividend distribution plan totaling a record RMB 5.7 billion in 2026, reaffirming its commitment to rewarding shareholders while fostering long-term value creation. With robust strategies in place, WuXi AppTec is poised to continue making significant strides in the pharmaceutical and life sciences sectors, ensuring they maintain their status as a leader in healthcare innovation, delivering vital treatments to patients globally.

Overall, WuXi AppTec's remarkable financial performance in 2025 sets a strong foundation for future growth, positioning the firm well to navigate ongoing challenges and capture new opportunities in the evolving healthcare landscape.